Clinical benefit of early phase clinical trial participation for advanced sarcoma patients | Zendy

Robin L. Jones | Zendy; David Olmos | Zendy; Khin Thway | Zendy; Cyril Fisher | Zendy; Nina Tunariu | Zendy; Sophie PostelVinay | Zendy; Michelle Scurr | Zendy; Johann S. de Bono | Zendy; Stan B. Kaye | Zendy; Ian Judson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

Author(s) -

Robin L. Jones,

David Olmos,

Khin Thway,

Cyril Fisher,

Nina Tunariu,

Sophie PostelVinay,

Michelle Scurr,

Johann S. de Bono,

Stan B. Kaye,

Ian Judson

Publication year - 2010

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-010-1484-9

Subject(s) - medicine , ifosfamide , clinical trial , sarcoma , trabectedin , phases of clinical research , surgery , toxicity , soft tissue sarcoma , progression free survival , chemotherapy , oncology , pathology , etoposide

Standard systemic treatment options for patients with advanced sarcoma are limited. Depending on the histological subtype, patients receive differing lines of therapy usually consisting of doxorubicin, ifosfamide and/or trabectedin. After progression on conventional therapies, some patients are offered more experimental options including Phase I clinical trials. The aim of this study was to evaluate the clinical benefit for sarcoma patients treated within the Phase I Unit of a single referral centre.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research